Gilead Sciences gains U.S. regulatory nod for YM BioSciences buy
Nasdaq-listed biopharmaceutical company Gilead Sciences has received U.S. antitrust clearance for its $510 million purchase of NYSE-listed drug developer YM BioSciences, according to a company statement.Washington – Nasdaq-listed biopharmaceutical company Gilead...To view the full article, register now.
Already a subscriber? Click here to view full article